This is an open label, multi-center, Phase 1/2 clinical trial in subjects with recurrent adenocarcinoma of the ovary who have been previously treated with a minimum of two courses of platinum-based chemotherapy, and up to two additional cytotoxic regimens that may also have included platinum (no more than four total lines of prior therapy), with or without bevacizumab, whose cancer has recurred within six months of the most recent platinum-based chemotherapy. All eligible subjects will receive VAL 083 i.v. in a once weekly cycle until disease progression, development of other unacceptable toxicity, death, withdrawal of consent, loss to follow-up, or Sponsor ending the study, whichever occurs first.

Start Date01 Mar 2021

Sponsor / Collaborator

Kintara Therapeutics, Inc.

ChiCTR2000041279

/ RecruitingPhase 4IIT

A single-arm, multicenter, exploratory, post-marketing clinical study of evaluating desquaxel for injection in the second-line treatmen

Start Date01 Dec 2020

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

NCT03970447

/ RecruitingPhase 2/3IIT

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.

Start Date30 Jul 2019

Sponsor / Collaborator

Polaris Group

[+6]

100 Clinical Results associated with Dianhydrodulcitol

100 Translational Medicine associated with Dianhydrodulcitol

100 Patents (Medical) associated with Dianhydrodulcitol

370

Literatures (Medical) associated with Dianhydrodulcitol

01 Nov 2025·MEAT SCIENCE

Quality characteristics of frankfurters influenced by lard-based diacylglycerol containing catechin during storage at 4 °C

Article

Author: Wang, Hui ; Kong, Baohua ; Chen, Qian ; Li, Yuexin ; Sun, Fangda ; Hui, Wenting ; Liu, Qian

Frankfurters formulated with either lard or diacylglycerol (DAG)-rich purified glycerolytic lard (PGL), with or without catechin, were vacuum-packed and stored at 4 °C for 28 days to evaluate their physicochemical and sensory properties. Results revealed that lard-based frankfurters exhibited significantly higher cooking loss (8.69 %) and released fat (0.63 %) compared to PGL-based frankfurters (5.13 % and 0.33 %) (P < 0.05). Over time, lard-based frankfurters experienced greater deterioration in color, texture, microstructure, and sensory quality, along with increased fat oxidation (0.18 to 1.54 mg/kg) and microbial growth (3.77 to 5.43 Log CFU/g) (P < 0.05). Notably, substituting lard with PGL significantly enhanced the L*-value, b*-value, texture, microstructure, and sensory quality during storage (P < 0.05). Furthermore, the inclusion of catechin in frankfurters further reduced cooking loss (8.69 to 6.74 % and 5.13 to 3.89 %) and released fat (0.63 to 0.54 % and 0.33 to 0.16 %) (P < 0.05) while improving color, texture, microstructure, and sensory quality (P < 0.05). Catechin also effectively inhibited fat oxidation (1.54 to 1.34 mg/kg and 1.86 to 1.51 mg/kg) and microbial growth (5.43 to 5.27 Log CFU/g and 5.37 to 5.09 Log CFU/g) in frankfurters during storage (P < 0.05). Overall, the incorporation of DAG and catechin improved the quality and shelf life of frankfurters during storage.

01 Jul 2025·LARYNGOSCOPE

Endoscopic Butterfly Myringoplasty: Comparison of Tragal Cartilage Graft and Dermal Allograft

Article

Author: Jeong, Hyun‐Taek ; Moon, In‐Seok ; Lee, Il‐Woo ; Kim, Seok‐Hyun

ABSTRACT:

Objectives:

Tympanic membrane perforation (TMP) is a common reason for visits to otolaryngology clinics. For decades, various surgical methods and grafts have been employed to treat TMP. This study aimed to compare the efficacy of tragal cartilage grafts (TCG) and dermal allografts (DAG) in myringoplasty for treating TMP.

Methods:

We retrospectively analyzed 80 patients who underwent endoscopic butterfly inlay myringoplasty between 2019 and 2022. The patients were divided into two groups based on the graft material used: TCG (n = 40) and DAG (n = 40).We compared preoperative and postoperative hearing results and surgical outcomes between the two groups.

Results:

Both the TCG and DAG groups demonstrated significant postoperative improvements in hearing. The air‐bone gap decreased from 11.87 to 7.74 dB in the TCG group (p = 0.01) and from 13.6 to 8.96 dB in the DAG group (p = 0.013). Similarly, the low‐tone average improved significantly: from 40.49 to 25.26 dB in the TCG group (p < 0.001) and from 38.33 to 25.15 dB in the DAG group (p < 0.001). The graft closure rates were comparable at 97.5% for TCG and 92.5% for DAG, indicating that both procedures are effective and similar in efficacy. However, the TCG group required more follow‐up visits (average of 4 vs. 2.6 for DAG).

Conclusions:

Both TCG and DAG techniques demonstrated comparable efficacy in terms of graft success rates and hearing improvement, with no significant differences in postoperative complications.

Level of Evidence:

01 Jul 2025·Waste and Biomass Valorization

Efficient Biofuel Production from Olive Pomace and Polyethylene Waste Blend via Pressurized Co-Pyrolysis: Optimization and Characterization

Author: Loubar, Khaled ; Harfi, Khalifa El ; Aboulkas, Adil ; Jellali, Salah ; Jeguirim, Mejdi ; Dahman, Hicham ; Kilani, Emna Berrich

Abstract: In this work, an exptl. investigation is performed in order to assess the pressurized co-pyrolysis of olive pomace (OP) and plastic wastes (high-d. polyethylene-HDPE).Different operating conditions were evaluated to determine the optimal parameters.In particular, pyrolysis tests were realized at various temperatures (350, 400, 450, 500, 550 and 600 °C) and reaction times (30, 45, 60 and 120 min).Results show that the interaction between the biomass and the plastic wastes has a significant effect on the final pressurized pyrolysis products.The OP/HDPE blend (1:1) pyrolysis generated more liquid fuel yield than individual components pyrolyzed sep.This result suggests a synergistic effect between OP and HDPE for the liquid fuel productionThe maximum oil yield obtained from OP pyrolysis and from HDPE pyrolysis was about 19.6%, 80.2% at 400 °C and 500 °C resp.However, this value from the pressurized pyrolysis was assessed to 57.4% at a temperature of 450 °C.The optimal residence time for OP and the mixture OP/HDPE (1:1) was 30 min, while the optimal residence time for HDPE was 45 min.The results of the oils qual. analyses indicate that adding HDPE into the OP pyrolysis led to a decrease in the oxygen-rich components and a significant rise in the hydrocarbons in the co-pyrolytic oils.This enhancement indicates that the inclusion of HDPE resulted in an upsurge in the hydrogen content while simultaneously causing a reduction in the oxygen content within the pressurized pyrolysis oils.This alteration is expected to yield a product with the potential for improved fuel characteristics.Graphical Abstract:

News (Medical) associated with Dianhydrodulcitol

14 Feb 2024

·www.prnewswire.com

Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal second quarter ended December 31, 2023, and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Announced the initiation of an open label 15-patient study in cutaneous metastatic breast cancer (CMBC) patients which is evaluating REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent, and is designed to test the 0.8 mg dose as well as optimize the study design in advance of a Phase 3 trial initiation. The primary endpoint in the study is Best Overall Objective Response Rate (bORR) (complete response or partial response) of the target treatment fields at any time from treatment up to, and including, week 24. The majority of the costs to run this study will be covered by the $2.0 million Small Business Innovation Research (SBIR) grant Kintara was awarded from the National Institutes of Health (NIH). (February 2024) Announced that Kintara's Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value and has engaged Ladenburg Thalmann & Co. Inc. to act as financial advisor for this process. (December 2023) Announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the current standards of care used to treat glioblastoma. As a result, Kintara terminated the development of VAL-083 and turned its focus to its REM-001 program. (October 2023) "We are pleased to have recently initiated our 15 patient REM-001 study for cutaneous metastatic breast cancer, a disease with little or no current treatment options" commented Robert E. Hoffman, Kintara's President and Chief Executive Officer. "We have strengthened our balance sheet primarily with net proceeds from our at-the-market (ATM) facility and aggressive cost-cutting efforts. We continue to evaluate strategic options with the goal of maximizing shareholder value." SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 SECOND QUARTER ENDED DECEMBER 31, 2023 As of December 31, 2023, Kintara had cash and cash equivalents of approximately $0.7 million. From January 1, 2024, to February 12, 2024, the Company has received net proceeds of approximately $6.1 million from the sale of common stock, primarily from its ATM facility. For the three months ended December 31, 2023, Kintara reported a net loss of approximately $1.0 million, or $0.24 per share, compared to a net loss of approximately $3.5 million, or $2.10 per share, for the three months ended December 31, 2022. The decreased net loss for the three months ended December 31, 2023, compared to the three months ended December 31, 2022, was largely attributed to lower research and development expenses which was primarily due to lower clinical development costs. General and administrative costs were also lower during the same period primarily due to a reduction in personnel. Kintara's financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the Company's website at: . ABOUT KINTARA Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing therapeutics for clear unmet medical needs with reduced risk development programs. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). Kintara has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications. For more information, please visit or follow us on X at @Kintara_Thera, Facebook and LinkedIn. SAFE HARBOR STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's REM-001 15-patient clinical trial in CMBC patients; the topline results of the GBM AGILE Study; and the Company's review of strategic alternatives. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the status of the Company's clinical trials; the topline results of the GBM AGILE Study; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and global unrest. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2023, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K. CONTACTS Investors Robert E. Hoffman Kintara Therapeutics [email protected] SOURCE Kintara Therapeutics

Financial StatementPhase 3Radiation Therapy

13 Nov 2023

·www.prnewswire.com

Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal first quarter ended September 30, 2023 and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the current standards of care used to treat glioblastoma. With this study outcome, Kintara is suspending the development of VAL-083 and turning its focus to its second program, REM-001. In addition to focusing on its REM-001 program, Kintara will evaluate a wide range of strategic options aimed at potentially maximizing shareholder value. (October 2023) Awarded a $2.0 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support the clinical development of REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent for the treatment of cutaneous metastatic breast cancer (CMBC). (June 2023) "We are looking forward to enrolling the first patient in our 15 patient REM-001 study for cutaneous metastatic breast cancer, a disease with little or no current treatment options" commented Robert E. Hoffman, Kintara's President and Chief Executive Officer. "The majority of study expenses will be covered by the $2 million National Institutes of Health grant we were awarded to support the further development of REM-001. We have undertaken efforts to significantly cut costs and are continuing to evaluate strategic options with the goal of maximizing shareholder value." SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 FIRST QUARTER ENDED SEPTEMBER 30, 2023 As of September 30, 2023, Kintara had cash and cash equivalents of approximately $0.2 million. In November 2023, the Company has received net proceeds of approximately 1.0 million from the sale of common stock, primarily from its at-the-market (ATM) facility. For the three months ended September 30, 2023, Kintara reported a net loss of approximately $3.0 million, or $1.83 per share, compared to a net loss of approximately $4.6 million, or $3.39 per share, for the three months ended September 30, 2022. The decreased net losses for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 was largely due to lower research and development expenses, primarily lower clinical development costs. General and administrative costs were also lower during the same period primarily due to reduced level of staffing. Kintara's financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the Company's website at: . ABOUT KINTARA Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara develops therapeutics for clear unmet medical needs with reduced risk development programs. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). Kintara has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications. For more information, please visit or follow us on X at @Kintara_Thera, Facebook and Linkedin. SAFE HARBOR STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials; the topline results of the GBM AGILE Study; and the Company's review of strategic alternatives. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the status of the Company's clinical trials; the topline results of the GBM AGILE Study; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and global unrest. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2023, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K. CONTACTS Investors Robert E. Hoffman Kintara Therapeutics [email protected] SOURCE Kintara Therapeutics

Financial StatementRadiation Therapy

31 Oct 2023

·www.prnewswire.com

Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study

- VAL-083 Did Not Perform Better Than Current Standards of Care - - Company Suspending Development of VAL-083, Shifting Focus to REM-001 Program and Other Strategic Opportunities - SAN DIEGO, Oct. 31, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the current standards of care used to treat glioblastoma. With this study outcome, Kintara is suspending the development of VAL-083 and turning its focus to its second program, REM-001. In addition to focusing on its REM-001 program, Kintara will evaluate a wide range of strategic options aimed at potentially maximizing shareholder value. "Glioblastoma represents a high unmet medical need, and patients with this disease have very few treatment options," said Robert E. Hoffman, President and Chief Executive Officer of Kintara. "We are very disappointed that the VAL-083 GBM AGILE Study preliminary results do not support continued development efforts to give patients additional treatment options. We sincerely appreciate the exceptional support from patients and their families as well as patient advocates, physicians and our employees who have been committed to the rigorous study of VAL-083. As we shift priorities, we look forward to enrolling our first patient in our 15-patient study of REM-001 in cutaneous metastatic breast cancer (CMBC). Additionally, we will conduct a thorough review of potential strategic opportunities for us to maximize shareholder value in the Company." "GBM AGILE is a rigorous mechanism for us to efficiently evaluate investigational drugs in a well-controlled, randomized setting," said Meredith Buxton, CEO and President of Global Coalition of Adaptive Research, Sponsor of GBM AGILE. "While we are disappointed that the preliminary results for VAL-083 did not show benefit over standard of care, GBM AGILE is operating as designed and we await final data for VAL-083 in 2024 to better understand if there are possible pathways for further development." All development activities and related costs for VAL-083 will be suspended while the Company awaits the full dataset from the GBM AGILE Study which is expected at the end of the first quarter/beginning of second quarter of calendar year 2024. At such time Kintara will analyze the full results as it seeks to maximize the value of the VAL-083 asset. Kintara expects to enroll the first subject in a 15-patient CMBC study around the end of calendar year 2023. The Company was recently awarded a $2 million grant from the National Institutes of Health (NIH) which is expected to cover the majority of the cost to run the CMBC study. In November 2022, the United States Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to Kintara's REM-001 Therapy for the treatment of patients with CMBC. REM-001 is a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications. ABOUT KINTARA Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs and reduced development risk. Kintara's focus is the development of REM-001 as a treatment for CMBC. For more information, please visit or follow us on X (formerly Twitter) at @Kintara_Thera, Facebook and LinkedIn. SAFE HARBOR STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials, the topline results of the GBM AGILE Study and the Company's review of strategic alternatives. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and global unrest. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2023, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K. CONTACTS Robert E. Hoffman Kintara Therapeutics [email protected] SOURCE Kintara Therapeutics

Fast TrackClinical ResultRadiation Therapy

100 Deals associated with Dianhydrodulcitol

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01	DB12873

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lung Cancer	China	Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd.	13 Sep 2020
Philadelphia chromosome positive chronic myelogenous leukemia	China	Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd.	13 Sep 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma Multiforme	Phase 3	United States	Kintara Therapeutics, Inc.	27 Oct 2017
Recurrent Glioblastoma	Phase 3	United States	Kintara Therapeutics, Inc.	27 Oct 2017
Recurrent Platinum-Resistant Ovarian Carcinoma	Phase 2	United States	Kintara Therapeutics, Inc.	01 Mar 2021
Recurrent Malignant Glioma	Phase 2	United States	Kintara Therapeutics, Inc.	01 Oct 2011
Ovarian Cancer	Phase 2	United States	Kintara Therapeutics, Inc.	-
Hematologic Neoplasms	Clinical	United States	National Cancer Institute	-
Solid tumor	Clinical	United States	National Cancer Institute	-
Diffuse Intrinsic Pontine Glioma	Preclinical	United States	Kintara Therapeutics, Inc.	21 Apr 2019
Medulloblastoma	Preclinical	United States	Kintara Therapeutics, Inc.	23 Feb 2016
Non-Small Cell Lung Cancer	Preclinical	Canada	Kintara Therapeutics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03138629 (CTNI-72, SNO2024)	Not Applicable	Recurrent Glioblastoma TERT \| PTEN \| TP53 ... View more	30	VAL-083 30 mg/m2/day	dsocxscpyh(axdbwecjzr) = The most frequent adverse events were consistent with prior experience, i.e., neutropenia uticlphlap (xbwhpmiedr ) View more	Positive	11 Nov 2024
NCT02717962 (CTNI-73, SNO2024)	Phase 2	Glioblastoma Multiforme PTEN \| EGFR \| TP53	34	VAL-083 30 mg/m2	ugezhefnvz(wrytdowgdk) = rtgjrvvkdv lfgrjonjni (qkvjowxtlh, 13.3 - 19.0) View more	Negative	11 Nov 2024
NCT03138629 (CTNI-71, SNO2024)	Not Applicable	Ependymoma \| Diffuse Midline Glioma \| Astrocytoma, IDH-Mutant IDHwt \| MAP2K1 \| ATRX ... View more	4	VAL-083	ftcukhpvbd(ueypajvtds) = wchivxydfi dskhdtnqvm (fbbueuzlur )	Positive	11 Nov 2024
NCT03138629 (AACR2023) Manual	Not Applicable	Recurrent Glioblastoma unmethylated MGMT promoter \| IDH wild type \| MSH6 mutation ... View more	24	VAL-083 30mg/m2 ± Bevacizumab	dskszepbqo(uzmcygvfvz) = VAL-083 was well tolerated and the main adverse events were consistent with prior experience, i.e., thrombocytopenia and neutropenia. ncqxhpooun (kehwnntieu )	Positive	14 Apr 2023
				VAL-083 30mg/m2 ± Bevacizumab (Patients without multifocal disease)
NCT03138629 (DDDR-36, SNO2022)	Not Applicable	Recurrent Glioblastoma unmethylated MGMT promoter \| IDH-WT \| TERT promoter mutation ... View more	14	VAL-083	uchnbtzkve(mezwajaxqv) = The main adverse event was thrombocytopenia consistent with prior experience gywyeidbiy (afxoywlkkk )	-	14 Nov 2022
NCT03050736 (CTNI-21, SNO2021)	Phase 2	Glioblastoma Multiforme MGMT-unmethylated	29	VAL-083 20 mg/m2/day	nujuwqwvlf(nlkkxtvpgp) = Sixteen (16/29; 55.2%) patients had died tjgrpnzinq (rdwqsowjjh ) View more	Positive	12 Nov 2021
				VAL-083 30 mg/m2/day
NCT02717962 (PRNewswire) Manual	Phase 2	Glioblastoma	89	VAL-083 (40 mg/m2/day)	enlxvseglo(ghvkhlvdey) = ukmsldfrey bmprpobgnf (whvgrlspiw, 6.1 - 9.0)	Positive	01 Jul 2021
				VAL-083 (receiving the treatment dose of 30 mg/m2/day on days 1, 2 and 3 of a 21-day cycle)	enlxvseglo(ghvkhlvdey) = wduhnutptb bmprpobgnf (whvgrlspiw, 5.9 - 9.9) View more
NCT03050736 \| NCT02717962 (AACR2020)	Phase 2	Glioblastoma Multiforme Second line	-	VAL-083	jtwrjycpou(rktjexmrud) = pkopwaeoff omhioidebg (zninftocvo )	Positive	15 Aug 2020
				VAL-083+Bevacizumab	jtwrjycpou(rktjexmrud) = mtphoeteok omhioidebg (zninftocvo )
NCT01478178 (DLM-10-001, ASCO2018)	Phase 1/2	Glioblastoma	45	Clinically active dose of VAL-083	ektewubnxw(bqicqhwydd) = xjepskeyai updkvuaghr (jnwpxwtcjf, 3.1 - 9.6)	Positive	01 Jun 2018
				Inactive dose of VAL-083	ektewubnxw(bqicqhwydd) = iqhkxqwieo updkvuaghr (jnwpxwtcjf )
NCT01478178 (AACR2016)	Phase 1/2	Recurrent Glioblastoma	55	VAL-083	lmstfjvypb(ussmkweqvg) = Observed myelosuppression is mild, with the exception of 1 patient previously treated with CCNU who developed grade 4 thrombocytopenia wthdxwhcaf (rgockpnnpt ) View more	Positive	15 Jul 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis